Table 288 Heme-iron and colorectal cancer risk. Results of meta-analyses and pooled analyses of prospective studies published after the 2005 SLR. Total Number of cohort Studies Heterogeneity Author, Year number Outcome Comparison RR (95%CI) P trend studies country, area (I2, p of cases Meta-analysis Colorectal 1.14(1.04–1.24) Highest vs Lowest 11.5%, 0.34 8 cancer 1mg/day 1.11(1.03-1.18) JPHC, NHS, HPFS, Men (3) 1.09 (0.92–1.29) 8.1%, 0.34 Highest vs Lowest NIH-AARP, NBSS, NLCS, SMC, IWHS North Women (6) 1.18 (1.01–1.38) 29.6%, 0.20 Highest vs Lowest America, 8269 Qiao, 2013 Europe and Asia 8 Colon cancer 1.14 (1.03–1.26) 11.9%, 0.69 Highest vs Lowest 6 Rectal cancer 1.18 (1.00–1.38) 0%, 0.86
Table 288 Heme-iron and colorectal cancer risk. Results of meta-analyses and pooled analyses of prospective studies published after the 2005 SLR. Author, Year Number of cohort studies Total number of cases Studies country, area Outcome Comparison RR (95%CI) P trend Heterogeneity (I2, p Meta-analysis Qiao, 2013 8 JPHC, NHS, HPFS, NIH-AARP, NBSS, NLCS, SMC, IWHS 8269 North America, Europe and Asia Colorectal cancer Highest vs Lowest 1mg/day 1.14(1.04–1.24) 1.11(1.03-1.18) 11.5%, 0.34 Men (3) Highest vs Lowest 1.09 (0.92–1.29) 8.1%, 0.34 Women (6) Highest vs Lowest 1.18 (1.01–1.38) 29.6%, 0.20 8 Colon cancer Highest vs Lowest 1.14 (1.03–1.26) 11.9%, 0.69 6 Rectal cancer 1.18 (1.00–1.38) 0%, 0.86